This is the authors' abstract. We don't add key points for this paper.
Background This post hoc analysis of MERCURY-3 evaluates factors associated with baseline ocular hyperemia and tolerability outcomes with netarsudil/latanoprost fixed combination (NET/LAT).Research design and methods MERCURY-3 was a prospective, randomized, double-masked, multicenter, Phase 3, European trial. Adults with open-angle glaucoma or ocular hypertension inadequately controlled on topical therapy were randomized to once-daily NET/LAT (n = 218) or bimatoprost/timolol fixed combination (BIM/TIM; n = 212) for 6 months. Patients were stratified by baseline ocular hyperemia status (none vs any grade) and associations with prior treatment, adverse events (AEs), and hyperemia evolution evaluated.Results In the NET/LAT arm, prior combination therapy was associated with a greater prevalence of baseline ocular hyperemia than prior monotherapy (distribution: p = 0.003). Patients with baseline hyperemia experienced higher rates of AEs (85% vs 63%), ocular treatment-related AEs (74% vs 39%), and conjunctival hyperemia (45% vs 26%) during treatment. Ocular hyperemia remained predominantly mild throughout follow-up, with a more stable severity trajectory linked to prior monotherapy compared with prior combination therapy. No comparable associations were observed with BIM/TIM.Conclusions Prior treatment complexity and baseline ocular hyperemia status are associated with tolerability outcomes during NET/LAT therapy. These exploratory findings suggest that earlier step-up after monotherapy could be associated with more favorable tolerability.Trial registration CT.gov identifier: NCT03284853.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Gábor Holló (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: